Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
暂无分享,去创建一个
William A. Lee | Mike Flint | Donald K. Nichols | Sina Bavari | Robert Jordan | Jeffrey R. Kugelman | Stuart T. Nichol | Travis K. Warren | Jay Wells | G. Palacios | R. Jordan | R. Mackman | S. Bavari | T. Cihlar | S. Nichol | S. Swaminathan | C. Spiropoulou | M. Flint | Kirsten M. Stray | Shan-Shan Chen | Jeffrey R Kugelman | R. Fearns | M. Clarke | V. Soloveva | D. Mayers | Elyse R. Nagle | R. Strickley | A. Ray | M. Perron | Joy Y. Feng | R. Bannister | Yeojin Park | D. Babusis | D. Siegel | H. Hui | Edward M. Doerffler | K. Chun | Lijun Zhang | Sean Neville | Ernest A. Carra | W. Lew | B. Ross | Q. Wang | Lydia Wolfe | O. Barauskas | Yili Xu | M. Lo | Travis Warren | L. McMullan | Willard Lew | Gustavo Palacios | Christina F. Spiropoulou | Veronica Soloveva | Tara A. Kenny | Michel Perron | Yili Xu | Michael O. Clarke | Tomas Cihlar | Jay B. Wells | N. Garza | Lisa S. Welch | C. Wilhelmsen | Douglas L. Mayers | Nate Larson | Kelly S. Stuthman | Sean A. van Tongeren | G. Donnelly | A. Shurtleff | Cary J. Retterer | D. Gharaibeh | Rouzbeh Zamani | Brett P. Eaton | Elizabeth C. Grimes | L. Gomba | D. Nichols | Jonathan E. Nuss | Iva Trancheva | Pamela Wong | Molly R Braun | Adrian S. Ray | Dustin Siegel | Edward Doerffler | Kwon Chun | Lijun Zhang | Sean Neville | Ernest Carra | Bruce Ross | Queenie Wang | Lydia Wolfe | Ona Barauskas | Roy Bannister | Robert Strickley | Swami Swaminathan | Travis K Warren | Darius Babusis | Laura K. McMullan | Tara Kenny | Ginger Donnelly | Nicole L. Garza | Michael K. Lo | Amy C. Shurtleff | Sean A. Van Tongeren | Richard L. Mackman | Hon C. Hui | Nate Larson | Dima Gharaibeh | Rouzbeh Zamani | Elizabeth Grimes | Laura Gomba | Catherine L. Wilhelmsen | Yeojin Park | Iva Trancheva | Pamela Wong | Molly R. Braun | Shan-Shan Chen | Rachel Fearns | Brett Eaton | J. Nuss
[1] M. Lado,et al. Sequelae of Ebola Virus Disease , 2018 .
[2] P. Formenty,et al. Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors — Final Report , 2017, The New England journal of medicine.
[3] G. Olinger,et al. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. , 2016, Antiviral research.
[4] D. Bausch,et al. Sequelae of Ebola Virus Disease, Kenema District, Sierra Leone. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] Jens H Kuhn,et al. Molecular Evidence of Sexual Transmission of Ebola Virus. , 2015, The New England journal of medicine.
[6] T. Fletcher,et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. , 2015, The Lancet. Infectious diseases.
[7] Jeffrey R. Kugelman,et al. Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. , 2015, Cell reports.
[8] Antonio Lazcano,et al. Structural Analysis of Monomeric RNA-Dependent Polymerases: Evolutionary and Therapeutic Implications , 2015, PloS one.
[9] Justine R. Smith,et al. Persistence of Ebola Virus in Ocular Fluid during Convalescence. , 2015, The New England journal of medicine.
[10] E. Dunn,et al. Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter , 2015, Journal of Virology.
[11] N. Snead,et al. Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates , 2015, Nature.
[12] Jon Cohen,et al. Infectious diseases. Ebola drug trials lurch ahead. , 2015, Science.
[13] T. Bell,et al. Characterization of clinical and immunological parameters during Ebola virus infection of rhesus macaques. , 2015, Viral immunology.
[14] Joshua C. Johnson,et al. Euthanasia Assessment in Ebola Virus Infected Nonhuman Primates , 2014, Viruses.
[15] J. Strong,et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ , 2014, Nature.
[16] S. Nichol,et al. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. , 2014, Antiviral research.
[17] S. Günther,et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. , 2014, Antiviral research.
[18] R. Lenk,et al. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. , 2014, Antiviral research.
[19] Gianluca Pegoraro,et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 , 2014, Nature.
[20] S. Noton,et al. Respiratory Syncytial Virus Polymerase Can Initiate Transcription from Position 3 of the Leader Promoter , 2013, Journal of Virology.
[21] Jens H. Kuhn,et al. Ebola Virus Genome Plasticity as a Marker of Its Passaging History: A Comparison of In Vitro Passaging to Non-Human Primate Infection , 2012, PloS one.
[22] Lisa Hensley,et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques , 2012, Proceedings of the National Academy of Sciences.
[23] Kayoko Ohura,et al. Species difference of esterase expression and hydrolase activity in plasma. , 2012, Journal of pharmaceutical sciences.
[24] S. Noton,et al. The Respiratory Syncytial Virus Polymerase Has Multiple RNA Synthesis Activities at the Promoter , 2012, PLoS pathogens.
[25] A. Ray,et al. Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides , 2012, Bioorganic & Medicinal Chemistry Letters.
[26] C. Kim,et al. Practical synthesis of 1′-substituted Tubercidin C-nucleoside analogs , 2012 .
[27] J. Arnold,et al. Identification of Multiple Rate-limiting Steps during the Human Mitochondrial Transcription Cycle in Vitro* , 2010, The Journal of Biological Chemistry.
[28] R. Bazzo,et al. Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine. , 2009, European journal of medicinal chemistry.
[29] William A. Lee,et al. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. , 2009, Molecular pharmaceutics.
[30] J. Kuhn,et al. Filoviruses: A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies , 2008, Emerging Infectious Diseases.
[31] M. Otto,et al. The Mechanism of Action of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methylcytidine Involves a Second Metabolic Pathway Leading to β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine 5′-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase , 2007, Antimicrobial Agents and Chemotherapy.
[32] C. Goldsmith,et al. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. , 2005, Virology.
[33] R. Shao,et al. Human microvascular endothelial cells immortalized with human telomerase catalytic protein: a model for the study of in vitro angiogenesis. , 2004, Biochemical and biophysical research communications.
[34] B. Simoneau,et al. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. , 2004, Nucleic acids research.